308 related articles for article (PubMed ID: 16207172)
21. New Approaches to Multi-Parametric HIV-1 Genetics Using Multiple Displacement Amplification: Determining the What, How, and Where of the HIV-1 Reservoir.
Patro SC; Niyongabo A; Maldarelli F; Kearney MF
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960744
[TBL] [Abstract][Full Text] [Related]
22. HIV "shock and kill" therapy: In need of revision.
Abner E; Jordan A
Antiviral Res; 2019 Jun; 166():19-34. PubMed ID: 30914265
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
24. High-mobility group box 1 protein induces HIV-1 expression from persistently infected cells.
Thierry S; Gozlan J; Jaulmes A; Boniface R; Nasreddine N; Strauss F; Maréchal V
AIDS; 2007 Jan; 21(3):283-92. PubMed ID: 17255735
[TBL] [Abstract][Full Text] [Related]
25. The multifactorial nature of HIV-1 latency.
Lassen K; Han Y; Zhou Y; Siliciano J; Siliciano RF
Trends Mol Med; 2004 Nov; 10(11):525-31. PubMed ID: 15519278
[TBL] [Abstract][Full Text] [Related]
26. Anti-gene peptide nucleic acid targeted to proviral HIV-1 DNA inhibits in vitro HIV-1 replication.
Pesce CD; Bolacchi F; Bongiovanni B; Cisotta F; Capozzi M; Diviacco S; Quadrifoglio F; Mango R; Novelli G; Mossa G; Esposito C; Ombres D; Rocchi G; Bergamini A
Antiviral Res; 2005 Apr; 66(1):13-22. PubMed ID: 15781127
[TBL] [Abstract][Full Text] [Related]
27. Attacking HIV provirus: therapeutic strategies to disrupt persistent infection.
Margolis DM; Archin NM
Infect Disord Drug Targets; 2006 Dec; 6(4):369-76. PubMed ID: 17168802
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 integration landscape during latent and active infection.
Cohn LB; Silva IT; Oliveira TY; Rosales RA; Parrish EH; Learn GH; Hahn BH; Czartoski JL; McElrath MJ; Lehmann C; Klein F; Caskey M; Walker BD; Siliciano JD; Siliciano RF; Jankovic M; Nussenzweig MC
Cell; 2015 Jan; 160(3):420-32. PubMed ID: 25635456
[TBL] [Abstract][Full Text] [Related]
29. Host factors regulating post-integration latency of HIV.
Williams SA; Greene WC
Trends Microbiol; 2005 Apr; 13(4):137-9. PubMed ID: 15817380
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 natural viral suppressors: control of viral replication in the absence of therapy.
Sajadi MM; Heredia A; Le N; Constantine NT; Redfield RR
AIDS; 2007 Feb; 21(4):517-9. PubMed ID: 17301571
[TBL] [Abstract][Full Text] [Related]
31. Clonal Expansion of Human Immunodeficiency Virus-Infected Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy.
Mullins JI; Frenkel LM
J Infect Dis; 2017 Mar; 215(suppl_3):S119-S127. PubMed ID: 28520966
[TBL] [Abstract][Full Text] [Related]
32. HIV reservoirs: the new frontier.
Iglesias-Ussel MD; Romerio F
AIDS Rev; 2011; 13(1):13-29. PubMed ID: 21412386
[TBL] [Abstract][Full Text] [Related]
33. HIV type-1 latency: targeted induction of proviral reservoirs.
Graci JD; Colacino JM; Peltz SW; Dougherty JP; Gu Z
Antivir Chem Chemother; 2009; 19(5):177-87. PubMed ID: 19483266
[TBL] [Abstract][Full Text] [Related]
34. HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-alpha + TSA.
Vandergeeten C; Quivy V; Moutschen M; Van Lint C; Piette J; Legrand-Poels S
Biochem Pharmacol; 2007 Jun; 73(11):1738-48. PubMed ID: 17386923
[TBL] [Abstract][Full Text] [Related]
35. Dual activity of phosphorothioate CpG oligodeoxynucleotides on HIV: reactivation of latent provirus and inhibition of productive infection in human T cells.
Scheller C; Ullrich A; Lamla S; Dittmer U; Rethwilm A; Koutsilieri E
Ann N Y Acad Sci; 2006 Dec; 1091():540-7. PubMed ID: 17341643
[TBL] [Abstract][Full Text] [Related]
36. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
[TBL] [Abstract][Full Text] [Related]
37. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation.
Williams SA; Chen LF; Kwon H; Ruiz-Jarabo CM; Verdin E; Greene WC
EMBO J; 2006 Jan; 25(1):139-49. PubMed ID: 16319923
[TBL] [Abstract][Full Text] [Related]
38. Viral latency and potential eradication of HIV-1.
Matreyek KA; Oztop I; Freed EO; Engelman A
Expert Rev Anti Infect Ther; 2012 Aug; 10(8):855-7. PubMed ID: 23030323
[TBL] [Abstract][Full Text] [Related]
39. TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells.
Thibault S; Imbeault M; Tardif MR; Tremblay MJ
Virology; 2009 Jun; 389(1-2):20-5. PubMed ID: 19447460
[TBL] [Abstract][Full Text] [Related]
40. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens.
Sarmati L; Parisi SG; Nicastri E; d'Ettorre G; Andreoni C; Dori L; Gatti F; Montano M; Buonomini AR; Boldrin C; Palù G; Vullo V; Andreoni M
J Med Virol; 2007 Jul; 79(7):880-6. PubMed ID: 17516532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
